EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Association Between Graves’ Disease and the Risk of Thyroid Carcinoma: The Role of Clinical, Metabolic, Hormonal, Immunological, and Ultrasound Biomarkers

Mihaela Andreea Precup, Andrei Korodi iD, Flaviu Ionut Faur iD, Paul Pasca iD, Draga-Maria Mandi iD, Dan Brebu, Cosmin Burta, Amadeus Dobrescu iD, Ciprian Duta

Metabolites · 17.08.2026 · 16 (8) · 580

DOI: 10.3390/metabo16080580 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 17.08.2026. Verfasst von Mihaela Andreea Precup und 8 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victor Babeș University of Medicine and Pharmacy Timișoara, VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY TIMISOARA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The relationship between Graves’ disease (GD) and thyroid carcinoma (TC) remains controversial, particularly regarding the predictive value of metabolic, hormonal, immunological, and ultrasound biomarkers. We performed a systematic review and meta-analysis to evaluate the prevalence of TC in patients with GD and to identify biomarkers associated with an increased risk of malignancy.

Methods

A systematic literature search of PubMed/MEDLINE, Scopus, Web of Science, Embase, and the Cochrane Library was conducted in accordance with PRISMA 2020. Primary studies providing direct evidence in patients with Graves’ disease or indirect evidence concerning thyroid carcinoma-associated biomarkers were considered. Owing to substantial differences in study populations, designs, exposures, and outcomes, quantitative pooling was restricted to sufficiently comparable estimates, while the remaining evidence was synthesized descriptively.

Results

Six primary studies were included. Two retrospective cohorts directly evaluated thyroid carcinoma in patients with Graves’ disease and included 1051 patients, of whom 317 had thyroid carcinoma. The remaining studies provided indirect evidence from patients with hyperthyroidism, population-based thyroid cancer cohorts, or genetic datasets. Because of substantial clinical and methodological heterogeneity, a single pooled estimate was not considered appropriate. Thyroid nodules and larger nodule size were associated with malignancy in Graves’ disease, while elevated triglycerides, reduced HDL cholesterol, and higher body mass index were associated with thyroid carcinoma in a surgically selected Graves’ disease cohort. Evidence concerning hormonal, immunological, inflammatory, and genetically determined metabolic markers was heterogeneous and largely indirect.

Conclusions

Thyroid carcinoma risk in Graves’ disease is heterogeneous and appears to be concentrated in patients presenting with suspicious ultrasound findings and adverse metabolic profiles. Ultrasound biomarkers remain the most robust predictors of malignancy, while metabolic biomarkers represent promising complementary tools for individualized risk stratification. Current evidence does not support the routine use of hormonal or immunological biomarkers as independent predictors of thyroid carcinoma. Large prospective multicenter studies using standardized biomarker assessment are required to validate these findings and optimize personalized surveillance strategies.

Schlagwörter

Stichwörter der Autor:innen

Graves’ diseasePRISMA 2020TRAbbiomarkerslipid profilemeta-analysismetabolic biomarkerspapillary thyroid carcinomasystematic reviewthyroid carcinomathyroid ultrasound

Autor:innen und Institutionen

  • Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania.
  • 2nd Surgery Clinic, Emergency Clinical County Hospital of Arad, 2-4 Andreny Karoly Str., 310037 Arad, Romania.
  • Department of Medicine, Faculty of Medicine, "Vasile Goldis" Western University of Arad, L. Rebreanu St. 86, 310048 Arad, Romania.
  • Researching Future Surgery II Research Center, Department X, Discipline of General Surgery II, Faculty of Medicine, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, R…
  • General Surgery Department, Coltea Clinical Hospital, Bulevardul Ion C. Brătianu 1, 030171 București, Romania.

ORCID-Profile: Andrei Korodi, Flaviu Ionut Faur, Paul Pasca, Draga-Maria Mandi, Amadeus Dobrescu

Förderung

  • Victor Babeș University of Medicine and Pharmacy Timișoara
  • VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY TIMISOARA

Zitieren

APA

Precup, M. A., Korodi, A., Faur, F. I., Pasca, P., Mandi, D. M., Brebu, D., Burta, C., Dobrescu, A., & Duta, C. (2026). Association Between Graves’ Disease and the Risk of Thyroid Carcinoma: The Role of Clinical, Metabolic, Hormonal, Immunological, and Ultrasound Biomarkers. Metabolites, 16(8), 580. https://doi.org/10.3390/metabo16080580

Vancouver

Precup MA, Korodi A, Faur FI, Pasca P, Mandi DM, Brebu D, et al. Association Between Graves’ Disease and the Risk of Thyroid Carcinoma: The Role of Clinical, Metabolic, Hormonal, Immunological, and Ultrasound Biomarkers. Metabolites. 2026;16(8):580. doi:10.3390/metabo16080580

BibTeX
@article{Precup2026,
  author = {Precup, Mihaela Andreea and Korodi, Andrei and Faur, Flaviu Ionut and Pasca, Paul and Mandi, Draga-Maria and Brebu, Dan and Burta, Cosmin and Dobrescu, Amadeus and Duta, Ciprian},
  title = {Association Between Graves’ Disease and the Risk of Thyroid Carcinoma: The Role of Clinical, Metabolic, Hormonal, Immunological, and Ultrasound Biomarkers},
  journal = {Metabolites},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {580},
  doi = {10.3390/metabo16080580}
}
Kostenlos starten →